Medications containing semaglutide have gained attention for their role in blood glucose management and weight loss. Originally developed to treat type 2 diabetes, semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood glucose, appetite and digestion. By helping people feel full for longer and reducing hunger, the medication can support weight management in eligible patients.
Ozempic is primarily approved for type 2 diabetes, while Wegovy is a semaglutide product approved for chronic weight management in eligible patients in certain countries. Although they contain the same active ingredient, their approved uses and dosing regimens differ.
Clinical trials, including the STEP programme investigating semaglutide 2.4 mg, have demonstrated substantial weight loss when treatment is combined with lifestyle interventions. These findings have strengthened the role of GLP-1 medications in the management of obesity, a complex condition influenced by biological, behavioural and environmental factors.
However, medication does not eliminate the importance of healthy eating. A balanced, nutrient-dense diet remains essential for maintaining nutritional adequacy, supporting metabolic health and preserving muscle during weight loss. Adequate protein, vegetables, fruits, whole grains and healthy fats can help individuals meet their nutritional requirements while reducing body weight.
Understanding the Side Effects
Semaglutide can cause gastrointestinal side effects, particularly when treatment begins or the dose increases. Common symptoms include nausea, vomiting, diarrhoea and constipation. These effects can reduce food intake and contribute to dehydration if fluids cannot be maintained.
More serious complications are possible, including pancreatitis, gallbladder problems and kidney injury associated with dehydration. People with diabetes may also require monitoring for changes in diabetic retinopathy, particularly when blood glucose levels improve rapidly. Persistent severe abdominal pain, repeated vomiting or other concerning symptoms require prompt medical assessment.
Who Needs Special Medical Assessment?
Semaglutide is not suitable for everyone. It should not be used for weight loss during pregnancy, and treatment should be reviewed when planning pregnancy. In the United States, Ozempic and Wegovy carry warnings concerning thyroid C-cell tumours observed in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
People with a history of pancreatitis, severe gastroparesis, gallbladder disease, kidney problems or diabetic eye disease should discuss the potential risks and monitoring requirements with their healthcare professional. Those taking insulin or sulfonylureas may require medication adjustments to reduce the risk of hypoglycaemia.
Why Nutrition Still Matters
Effective weight management involves more than reducing appetite or achieving a lower number on the scales. Maintaining muscle mass, preventing nutrient deficiencies, developing sustainable eating habits and supporting long-term health are equally important considerations.
Individualised nutrition care can help patients manage gastrointestinal symptoms, maintain adequate protein and fluid intake, and establish eating patterns that remain practical during and after treatment. Physical activity, including resistance exercise when appropriate, can also support muscle preservation and overall health.
Ultimately, semaglutide can be an effective medical tool for eligible patients, but it should not be viewed as a substitute for balanced nutrition or professional care. The most appropriate approach combines evidence-based medication when indicated with sustainable lifestyle habits and ongoing medical supervision.
The goal of weight management is not simply to lose weight, but to improve health, preserve nutritional well-being and achieve sustainable results.
Editorial health note: This article is for general educational purposes and does not replace individual medical advice. Medication decisions should be made with a qualified healthcare professional, following the product information applicable in the patient’s country.
